ArticleProstate international2021
Radiation-induced haemorrhagic cystitis after prostate cancer radiotherapy: factors associated to hospitalization and treatment strategies.
Article in Prostate international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- Senescence-Driven Inflammation and Immune Dynamics in the Progression of Radiation Cystitis.Cells · 2026Article
- Postoperative complications following simple cystectomy for radiation-induced bladder dysfunction compared to radical cystectomy: A matched cohort study.Central European journal of urology · 2026Article
- The dose-volume histogram-based evaluation of predictors for gross hematuria after postprostatectomy radiotherapy.Prostate international · 2025Article
- Management and recurrence patterns of radiation-induced cystitis with hematuria: a persistent clinical challenge.World journal of urology · 2025Article
- Exploring the dosimetric advantages of a novel multi-modality radiotherapy platform in prostate cancer.Physical and engineering sciences in medicine · 2025Article
- Patient Reported Outcomes and Treatment-Associated Complications as a Consideration in Selecting Localized Prostate Cancer Management.Research and reports in urology · 2025Review
- Radiation-Induced Hemorrhagic Cystitis in Prostate Cancer Survivors: The Hidden Toll.Medicina (Kaunas, Lithuania) · 2024Article
- Advancements in Understanding and Managing Radiation Cystitis: A Comprehensive Review.Current urology reports · 2024Review
- A novel nomogram based on inflammation biomarkers for predicting radiation cystitis in patients with local advanced cervical cancer.Cancer medicine · 2024Article
- Does renal failure worsen radiation cystitis following radical prostatectomy?International urology and nephrology · 2023Article
- Article
- Patient age as a predictive factor in biochemical recurrence following brachytherapy: Oncological outcomes at a single center.Prostate international · 2022Article
- Chronological changes of lower urinary tract symptoms after low-dose-rate brachytherapy for prostate cancer using SpaceOAR® system.Prostate international · 2022Article
- Understanding Molecular Mechanisms and Identifying Key Processes in Chronic Radiation Cystitis.International journal of molecular sciences · 2022Review
- Analysis of Clinicopathological Factors Associated with Radiation-Induced Cystitis in Patients with Cervical Cancer.Journal of healthcare engineering · 2022Article
- Comparison of Estimated Late Toxicities between IMPT and IMRT Based on Multivariable NTCP Models for High-Risk Prostate Cancers Treated with Pelvic Nodal Radiation.International journal of particle therapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLate onset of radiation-induced haemorrhagic cystitis (RHC) after radiation therapy (RT) for prostate cancer (PCa) may present or evolve severely, requiring hospitalization with invasive interventions. In the present study, we have analysed the prevalence and risk factors associated with the onset of RHC.
methodsFrom January 2002 to May 2017, 1421 patients undertook RT for PCa as a primary, adjuvant, or salvage treatment option. RHC presented in 5.6% (n = 80) of the patients; the diagnosis was based on clinical and endoscopic characteristics. Variables in observation included patients, tumours, and RT-dosimetry characteristics. Patients with a previous history of bladder cancer were excluded. Univariate (Student
resultsThere were 80 patients with a mean age at RT of 70.1 years (SD 6.4), mean time lag to RHC of 43.9 months (SD 37.5). Median Emergency attendance was two and three times for patients without/with hospitalization, respectively. There were in total 64 admissions with invasive treatment required in 26/36 (72.2%) of the patients hospitalised, including transurethral fulguration in 22 and radical cystectomy in 5. Patients at higher risk of hospitalization were those undertaking antiplatelet/anticoagulant treatment (HR:3.30; CI 95%:1.53-3.30;
conclusionNearly half of patients presenting RHC may require invasive treatment including cystectomy. Risk factors associated with hospitalization are patients undertaking antiplatelet/coagulant treatment and bladder V70 > 29% in salvage RT patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.